{
  "text": "Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma.\n The efficacy and safety of m-[131I]iodobenzylguanidine ([131I]MIBG) were assessed in 15 patients with malignant pheochromocytomas in a nonrandomized, single arm trial, in which patients were treated with [131I]MIBG (SA, 740 megabequerel/mg) every 3 months.\n Seven of these patients had bone and soft tissue metastases, 4 had only soft metastases, and 4 had only bone metastases.\n The follow-up period ranged from 6-54 months; the number of doses ranged from 2-11, with 2.9 (78.4 mCi) to 9.25 gigabequerel (GBq) (250 mCi)/administration and a cumulative activity from 11.1-85.90 GBq (300-2322 mCi).\n The absorbed cumulative dose in tumors ranged from 12-155 Gy.\n A beneficial effect of the treatment was observed in 9 patients (60%).\n No complete remission of the disease was observed.\n Seven patients died during the study, among whom 4 never responded to the treatment.\n Seven had hormonal responses (4 complete and 3 partial), with a duration ranging from 5-48 months.\n Among these patients, 4 relapsed, and 3 died within 3 months.\n Five patients had partial tumoral responses mainly located in soft tissues and for a duration ranging from 29-54 months.\n All patients with a hormonal response had objective improvement in clinical status and blood pressure.\n There was no clear-cut relationship between the cumulative dose and the responses.\n The main side-effect observed in 1 patient with widespread bone metastases after three doses (12.9 GBq) was a pancytopenia, which resolved after treatment was discontinued.\n This study suggests that repeated [131I]MIBG treatment could be effective in patients with advanced malignant pheochromocytoma.",
  "category": "C04"
}